- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 19.12.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 288 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 20.11.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | Vaso announces divestiture of VasoHealthcare for $0.8M | 1 | Seeking Alpha | ||
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 469 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 266 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 02.09.25 | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 448 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen | |
| 15.05.25 | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 301 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03.25 | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 276 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 39,275 | +7,93 % | SHORT SQUEEZE bei Gerresheimer? WACHSEN Bayer und MustGrow bald gemeinsam? | Während die Börse den Iran-Krieg und steigende Energiepreise verdauen, zieht plötzlich die Aktie von Gerresheimer spürbar an. News gibt es keine. Ist ein Short Squeeze möglich? Leerverkäufer hatten... ► Artikel lesen | |
| ASTRAZENECA | 169,50 | +1,13 % | DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11500 Pence belassen. Der Krebs-Antikörper Enhertu stehe im Konkurrenzvergleich... ► Artikel lesen | |
| EYEPOINT | 13,190 | +0,19 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,86 | -0,09 % | Ionis Pharmaceuticals skizziert Strategie für 2026: TRYNGOLZA-Expansion und wichtige Studiendaten im Fokus | ||
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| CSPC PHARMA | 1,034 | +0,98 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE ... | ||
| SELLAS LIFE SCIENCES | 5,370 | +3,07 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,290 | -0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,275 | +3,32 % | Acadia Pharmaceuticals beruft Jonathan M. Poole in den Verwaltungsrat | ||
| MADRIGAL PHARMACEUTICALS | 372,70 | -0,19 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ENZON PHARMACEUTICALS | 0,001 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock | ||
| OPUS GENETICS | 4,345 | +5,59 % | Opus Genetics GAAP EPS of -$0.80, revenue of $14.2M | ||
| CHUGAI PHARMACEUTICAL | 51,90 | -1,89 % | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,700 | +0,43 % | Savara receives FDA day 74 letter for autoimmune PAP drug |
VASO CORPORATION gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VASO CORPORATION finden Sie auf Wallstreet Online.